The curiously suspicious: a role for Epstein-Barr virus in lupus

被引:72
作者
Harley, J. B.
Harley, I. T. W.
Guthridge, J. M.
James, J. A.
机构
[1] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA
[2] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK 73104 USA
[3] Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK 73104 USA
[4] Vet Affairs Med Ctr, Oklahoma City, OK 73104 USA
关键词
cross-reactive antibodies; Epstein-Barr virus; environmental risk factors; etiology; molecular mimicry; review; systemic lupus erythematosus;
D O I
10.1177/0961203306070009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
While the events initiating the development of autoantibodies in systemic lupus erythematosus (SLE) have not yet been convincingly established, newly developed tools for molecular investigation make such an undertaking increasingly practical. Applied to the earliest events in the sequence culminating in lupus autoimmunity, we present a critical potential role for Epstein-Barr virus (EBV) in the development and perhaps perpetuation of SLE. The expected properties for an environmental risk factor for SLE are found in this vir-us and the human host response against it. Existing data show the molecular progression to autoimmunity observed in SLE patient sera, the discovery of the first autoimmune epitopes in the Sm and Ro autoantigen systems, and the possible emergence of these autoantibodies from the heterologous antibodies against Epstein-Barr nuclear antigen-1 (EBNA-1). Further, existing data demonstrate association of SLE with EBV infection, even preceding the development of autoimmunity. Finally, the data are consistent with a proposed model of lupus pathogenesis that begins with antibodies to EBNA-1, predisposing to immune responses that develop crossreactive autoantibodies that culminate in the development of SLE autoimmunity.
引用
收藏
页码:768 / 777
页数:10
相关论文
共 68 条
[1]  
Arbuckle MR, 1999, SCAND J IMMUNOL, V50, P447
[2]   Development of autoantibodies before the clinical onset of systemic lupus erythematosus [J].
Arbuckle, MR ;
McClain, MT ;
Rubertone, MV ;
Scofield, RH ;
Dennis, GJ ;
James, JA ;
Harley, JB .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (16) :1526-1533
[3]  
Arbuckle MR, 1998, J INVEST MED, V46, P58
[4]   Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus [J].
Baechler, EC ;
Batliwalla, FM ;
Karypis, G ;
Gaffney, PM ;
Ortmann, WA ;
Espe, KJ ;
Shark, KB ;
Grande, WJ ;
Hughes, KM ;
Kapur, V ;
Gregersen, PK ;
Behrens, TW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (05) :2610-2615
[5]   The emerging role of interferon in human systemic lupus erythematosus [J].
Baechler, EC ;
Gregersen, PK ;
Behrens, TI .
CURRENT OPINION IN IMMUNOLOGY, 2004, 16 (06) :801-807
[6]   Phenotypic and functional analysis of EBV-specific memory CD8 cells in SLE [J].
Berner, BR ;
Tary-Lehmann, M ;
Yonkers, NL ;
Askari, AD ;
Lehmann, PV ;
Anthony, DD .
CELLULAR IMMUNOLOGY, 2005, 235 (01) :29-38
[7]   Systemic lupus erythematosus and herpes virus infection: three new observations [J].
Bezanahary, H ;
Inaoui, R ;
Allot, V ;
Ly, K ;
Rogez, S ;
Liozon, E ;
Loustaud, V ;
Soria, P ;
Vidal, E .
REVUE DE MEDECINE INTERNE, 2002, 23 (12) :1018-1021
[8]  
BHIMMA R, 1995, S AFR MED J, V85, P899
[9]   Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals [J].
Caldwell, RG ;
Wilson, JB ;
Anderson, SJ ;
Longnecker, R .
IMMUNITY, 1998, 9 (03) :405-411
[10]  
Cooper GS, 1998, ARTHRITIS RHEUM, V41, P1714, DOI 10.1002/1529-0131(199810)41:10<1714::AID-ART3>3.3.CO